• Samsung Bioepis has recently relaunched BYOOVIZ (ranibizumab-nuna) in the US in partnership with Harrow, giving Harrow responsibility for commercializing this FDA-approved interchangeable Lucentis-referencing biosimilar for wet AMD, retinal vein occlusion-related macular edema, and myopic choroidal neovascularization.
• This move expands Harrow’s presence in the roughly US$9.00 billion US anti-VEGF market and directly addresses the high cost burden of standard retinal biologic therapies.
• We’ll now examine how Harrow’s exclusive role commercializing BYOOVIZ, an interchangeable Lucentis biosimilar, could reshape its broader investment narrative.

AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Harrow Investment Narrative Recap

To own Harrow, you have to believe that its focused ophthalmic portfolio can support sustained revenue growth while new launches offset dependence on a few flagship brands. The BYOOVIZ relaunch is a meaningful short term catalyst because it gives Harrow a higher profile foothold in the roughly US$9.00 billion US anti VEGF market, but it also heightens execution and pricing risk around its biosimilar expansion strategy.

Among recent announcements, Harrow’s reaffirmed 2026 revenue guidance of US$350 million to US$365 million stands out alongside this BYOOVIZ news. Together, they underscore how much the current investment case leans on successful commercialization of new products like BYOOVIZ, OPUVIZ, and relaunched brands such as VERKAZIA, while leaving little room for missteps in converting these launches into sustained, profitable growth.

Yet beneath the growth story, investors should also be aware that pricing and reimbursement pressure could...

Harrow's narrative projects $784.8 million revenue and $246.0 million earnings by 2029. This requires 42.9% yearly revenue growth and a $261.0 million earnings increase from -$15.0 million today.

Uncover how Harrow's forecasts yield a $68.38 fair value, a 59% upside to its current price.

Exploring Other Perspectives

Compared with the baseline view, the most cautious analysts saw more risk that new launches might underperform, even while assuming about 38% annual revenue growth and US$139.6 million in earnings by 2029, so you may want to weigh how BYOOVIZ could either ease or reinforce those concerns.

Explore 3 other fair value estimates on Harrow - why the stock might be worth just $59.00!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Harrow research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Harrow research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Harrow's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 41 companies with promising cash flow potential yet trading below their fair value.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.